Who is sponsoring NCT02655653?

NCT02655653 is sponsored by Montefiore Medical Center.

What drugs are being tested in NCT02655653?

Interventions: Epsilon-aminocaproic acid administered, Tranexamic Acid administered.

What is the status of NCT02655653?

NCT02655653 is currently COMPLETED.

Last reviewed 2020-06-02 · How we verify

A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery

NCT02655653 Phase 3 COMPLETED Results posted

The investigators primary objective is to compare the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing bleeding and transfusion in cardiac surgery, with the hypothesis that TA is more effective. The investigators also seek to further examine the clinical benefits and adverse effects profiles of epsilon-aminocaproic acid and tranexamic acid.

Details

Lead sponsor	Montefiore Medical Center
Phase	Phase 3
Status	COMPLETED
Enrolment	114
Start date	2008-10
Completion	2015-10

Conditions

Bleeding

Interventions

Epsilon-aminocaproic acid administered
Tranexamic Acid administered

Primary outcomes

Chest Tube Drainage — 4 hours, 8 hours, 12 hours, 24 hours
Chest tube drainage are collected from the nursing records, every 4th hourly the amount fluid collected is reported in the collection sheets.
Median Amount of Blood Products Used — 24 hours after surgery
Four types of blood products may be given through blood transfusions: whole blood, red blood cells, platelets, and plasma